Esperion Therapeutics, Inc. ESPR NASDAQ

Esperion Therapeutics, Inc. (ESPR) reported total assets of $465.89M and total liabilities of $767.85M for fiscal year 2025, resulting in total equity of $-301.97M.

The company held $167.85M in cash and short-term investments. Total debt stood at $548M, with net debt of $380.15M. The Debt-to-Equity (D/E) ratio was -1.81 (conservative).

Current ratio is 0.56, which may signal tight short-term liquidity. Interest coverage is 0.7x (weak).

Criteria supported by this page:

• HEALTH (0/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (58/100) — Total assets $465.89M and equity $-301.97M support the company's competitive scale
• VALUE (94/100) — Debt-to-Equity -1.81 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 45/100 with 2/7 criteria passed.

ITCI

Intra-Cellular Therapies, Inc.

$131.87

+0.00%

NBIX

Neurocrine Biosciences, Inc.

$131.44

+0.48%

ELAN

Elanco Animal Health Incorporated

$23.23

-3.65%

CTLT

Catalent, Inc.

$63.48

+0.00%

ALKS

Alkermes plc

$33.22

-1.92%

INVVY

Indivior PLC

$21.85

+0.00%

PBH

Prestige Consumer Healthcare Inc.

$57.57

+1.61%

PAHC

Phibro Animal Health Corporation

$55.01

-6.79%